ka2507
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2017 (NCT03008018)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Histone deacetylase 2INHIBITOR
HDAC2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- hdac6 inhibitor
- ka2507
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04186156 | Phase 1/Phase 2 (Phase 2) | Jan 31, 2020 | Karus Therapeutics Limited, University of London |
| NCT03008018 | Phase 1 | Mar 1, 2017 | Karus Therapeutics Limited |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Karus Therapeutics Limited | For profit | 2 | 2 | 2 | 2017 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2020 |
2 organizations
Page 1 / 1